Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
de novo facioscapulohumeral muscular dystrophy a severe subtype driven by d4z4 repeat contractions
Original title: “De Novo Facioscapulohumeral Muscular Dystrophy: A Severe Subtype Driven by D4Z4 Repeat Contractions.”
response to the letter to the editor regarding mortality associated with facioscapulohumeral muscular dystrophy a systematic literature review
Original title: “Response to the letter to the editor regarding "Mortality associated with facioscapulohumeral muscular dystrophy: A systematic literature review".”
Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
Original title: “Epicrispr, Infinimmune snag combined $165M in VC cash”
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Original title: “Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease”